Fulgent Genetics (FLGT) Cash & Equivalents (2015 - 2026)

Fulgent Genetics has disclosed Cash & Equivalents across 12 years of filings, most recently posting $26.3 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 70.07% year-over-year to $26.3 million; the TTM figure through Jun 2026 stood at $26.3 million (down 70.07% YoY), while the FY2025 annual figure was $50.2 million, down 8.98% from the prior year.
• Cash & Equivalents came in at $26.3 million for Q2 2026 at Fulgent Genetics, up from $23.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $353.1 million in Q1 2022 to a low of $23.4 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $91.8 million, with a median of $66.7 million recorded in 2023.
• Year-over-year, Cash & Equivalents soared 133.11% in 2022 and sank 81.26% in 2023.
• Over 5 years, Cash & Equivalents stood at $79.5 million in 2022, then gained by 22.6% to $97.5 million in 2023, then tumbled by 43.43% to $55.1 million in 2024, then declined by 8.98% to $50.2 million in 2025, then tumbled by 47.59% to $26.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $26.3 million in Q2 2026, $23.4 million in Q1 2026, and $50.2 million in Q4 2025.